Purpose: Peripheral nerve stimulation (PNS) is a rapidly expanding field within neuromodulation; however, there is limited data on therapeutic efficacy. This study describes the indications and clinical outcomes for patients undergoing PNS for chronic pain states.
Patients And Methods: This is a retrospective case series of adults undergoing PNS implantation from 2004 to 2017 at an academic medical center. The primary outcomes were changes in numeric rating scale (NRS) pain scores, opioid utilization in oral morphine milligram equivalent (MME), and self-reported patient functioning at 6 months postoperatively. Infectious and device-related complications were also assessed.
Results: A total of 72 patients underwent PNS implantation, including 59 patients that received a preceding PNS trial (59/78; 76% progression rate) and 13 that did not receive a PNS trial. The most common indication for stimulation was occipital neuralgia (47%) followed by lower-extremity neuropathies (17%). PNS implantation was associated with 6-month reductions in pain scores (7 [6, 8] baseline vs. 4 [2, 5] 6 months; P < 0.001) and opioid utilization (eg, median 60 [31, 104] vs. 18 [0, 52] MME among those with baseline opioid use; P < 0.001). Median functional improvement was 73% (50%, 88%). Seven patients (10%) suffered a postoperative surgical site infection at a median of 50 (30, 124) days, of which five devices were removed.
Conclusion: Peripheral nerve stimulation was associated with reduced pain scores, lower opioid utilization, and improved patient function at 6 months. These data support PNS as a potentially effective nonopioid analgesic modality in chronic pain, though prospective multicenter evaluation is warranted to evaluate longer-term outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/papr.12968 | DOI Listing |
Neuromodulation
December 2024
CHU de Poitiers, Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery Lab, Poitiers, France; CHU de Poitiers, Spinal Neurosurgery, Neuromodulation & Surgery for Handicap, Poitiers, France; Université de Poitiers, Prime Institute UPR 3346, CNRS, ISAE-ENSMA, Poitiers, France.
Background: Peripheral nerve stimulation (PNS) has emerged as a minimally invasive percutaneous procedure addressing neuropathic pain. However, the percutaneous cylindrical lead ultrasound-guided implantation procedure requires expertise that limits widespread PNS utilization. To overcome these challenges, a microinvasive endoscopy device has very recently been developed, enhancing the precision of PNS implantation by providing accurate visualization of the targeted nerve.
View Article and Find Full Text PDFFront Neurosci
November 2024
Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia.
Unlabelled: Limb amputation results in such devastating consequences as loss of motor and sensory functions and phantom limb pain (PLP). Neurostimulation-based approaches have been developed to treat this condition, which provide artificial somatosensory feedback such as peripheral nerve stimulation (PNS), spinal cord stimulation (SCS), and transcutaneous electrical nerve stimulation (TENS). Yet, the effectiveness of different neurostimulation methods has been rarely tested in the same participants.
View Article and Find Full Text PDFPain Physician
November 2024
Norman J. Dozier Pain Management, Abilene, Texas.
Background: Low back pain is a highly prevalent condition with substantial costs. Superior cluneal neuralgia is present in up to 14% of low back pain cases. This etiology of back pain is often overlooked because the symptoms of superior cluneal neuralgia manifest similarly to those of other conditions, such as radiculopathy and sacroiliac joint pain.
View Article and Find Full Text PDFPain Ther
November 2024
SPR Therapeutics, Cleveland, OH, USA.
Stereotact Funct Neurosurg
November 2024
Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA.
Introduction: Postherpetic neuralgia (PHN) is a pain syndrome that develops within few months after the acute herpetic outbreak. The pain may be accompanied by specific cutaneous signs in the distribution of affected dermatomes and feel unbearable reaching up to 9-10/10 on visual analog scale (VAS). Despite the introduction of new medications, drug resistance develops in at least 50% of cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!